iOnctura bolsters management team with senior appointments

Michael Lahn appointed Chief Medical Officer Zoë Johnson appointed Chief Scientific Officer Geneva, Switzerland, 12 March 2019:  iOnctura SA, the late stage preclinical immuno-oncology company, announced today the completion of its executive leadership team with the appointments of Michael Lahn as Chief Medical Officer (CMO) and Zoë Johnson as Chief Scientific Officer (CSO). Michael Lahn … Continue reading “iOnctura bolsters management team with senior appointments”

iOnctura selected for an oral presentation at 2019 AACR Annual Meeting

Geneva, Switzerland, 28th February 2019:  iOnctura SA, a late stage preclinical immuno-oncology company, announced today that its abstract (abstract # 1781) entitled “Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies” has been selected for an oral presentation at the American Association for Cancer Research Annual Meeting 2019 … Continue reading “iOnctura selected for an oral presentation at 2019 AACR Annual Meeting”

By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.

GET IN TOUCH